The Purpose of this Funding Opportunity Announcement is to solicit applications to rapidly implement early clinical trials using native and/or engineered monoclonal antibodies (mAbs) to achieve a drug-free sustained virologic remission in HIV infected individuals.
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-18-022.htmlAdditional Information of Eligibility:
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U. S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U. S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.Full Opportunity Web Address:http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-18-022.htmlContact: Agency Email Description:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster Agency Email: Date Posted:
2018-06-28Application Due Date: Archive Date: